![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
UK Shareholder Meetings Calendar - Next 7 Days
Monday 23 AprilForeign & Colonial Investment Trust BioquellMicrogenHgCapital
Read moreFri, 03rd Dec 2021 13:23
Monday 23 AprilForeign & Colonial Investment Trust BioquellMicrogenHgCapital
Read moreLONDON (Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Monday annual losses widened due to increased and
Read moreLONDON (Alliance News) - Pharmaceutical firm Hutchison China Meditech Ltd has started a phase Ib/II proof-of-concept study for its proposed brain cancer treatment is being in
Read more(ShareCast News) - Hutchison China MediTech presented data from a recent Phase I, first-in-human, dose escalating study of the safety, tolerability and pharmacokinetics and pharmacodynamics of single and multiple doses of HMPL-523 on Monday, to the Annual Meeting of the American College of Rheumatol
Read more(ShareCast News) - Hutchison China MediTech's prescription drug joint-venture received $59.5m on Friday from the Shanghai government under its land compensation agreement. The joint-venture with a subsidiary of Shanghai Pharmaceuticals, Shanghai Hutchison Pharmaceuticals, entered into a compensation
Read more(ShareCast News) - The wife of Hutchison China MediTech (Chi-Med) director Christopher Nash has swooped into the market to pick up a few of the company's shares a after hearing good reports on the China-based biopharma outfit's recent interim results and bulging drug pipeline. Mrs Nash, wife of the
Read more(ShareCast News) - Hutchison China MediTech reported its interim results for the six months to 30 June on Tuesday, with group revenue up 27% to $104.5m, from $82.5m. The AIM-traded firm said net income attributable to Chi-Med was $0.5m, significantly down from $15.9m a year ago, reflecting a sharp i
Read more(ShareCast News) - Healthcare group Hutchison China MediTech (Chi-Med) announced on Monday the start of a Phase II expansion of its ongoing TATTON trial. The AIM-traded firm said the TATTON trial is evaluating the selective c-Met inhibitor savolitinib in epidermal growth factor receptor (EGFR) mutan
Read more